233 related articles for article (PubMed ID: 19147689)
21. [Cardiac dysfunction induced by trastuzumab].
Campone M; Bourbouloux E; Fumoleau P
Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
[TBL] [Abstract][Full Text] [Related]
22. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
25. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure.
Walji N; Bhatt L; Dhallu S; Fernando IN
Breast; 2008 Aug; 17(4):423-5. PubMed ID: 18479923
[TBL] [Abstract][Full Text] [Related]
26. Management of trastuzumab-related cardiac dysfunction.
Carver JR
Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab-induced cardiomyopathy.
Guglin M; Cutro R; Mishkin JD
J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
[TBL] [Abstract][Full Text] [Related]
28. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
[TBL] [Abstract][Full Text] [Related]
29. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
30. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
[TBL] [Abstract][Full Text] [Related]
31. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
32. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
33. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
[TBL] [Abstract][Full Text] [Related]
34. [Cardiac safety of trastuzumab in adjuvant: a review across 53 observations].
Tanz R; Mahfoud T; Bazine A; Khmamouch R; Bensouda Y; Ismaili N; Benjaafar N; El Gueddari BK; Ichou M; Errihani H
J Gynecol Obstet Biol Reprod (Paris); 2011 Apr; 40(2):144-8. PubMed ID: 21227599
[TBL] [Abstract][Full Text] [Related]
35. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
36. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.
Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J
Oncology; 2013; 85(4):228-34. PubMed ID: 24081024
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery.
Murray LJ; Ramakrishnan S; O'Toole L; Manifold IH; Purohit OP; Coleman RE
Breast; 2010 Oct; 19(5):339-44. PubMed ID: 20226661
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
Farolfi A; Melegari E; Aquilina M; Scarpi E; Ibrahim T; Maltoni R; Sarti S; Cecconetto L; Pietri E; Ferrario C; Fedeli A; Faedi M; Nanni O; Frassineti GL; Amadori D; Rocca A
Heart; 2013 May; 99(9):634-9. PubMed ID: 23349345
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
Gianni L; Salvatorelli E; Minotti G
Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant targeted therapy in early breast cancer.
Mackey J; McLeod D; Ragaz J; Gelmon K; Verma S; Pritchard K; Laing K; Provencher L; Charbonneau LF
Cancer; 2009 Mar; 115(6):1154-68. PubMed ID: 19165856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]